CellDetect urine test for detecting bladder cancer meets primary endpoint in multi-center clinical study
BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today that a blinded, multi-center clinical study of the CellDetect non-invasive test for detecting bladder cancer in urine, successfully achieved the study's primary endpoint for effectively detecting the recurrence of bladder cancer in subjects with a history of the disease.